維羅納製藥 VRNA 深 滬
等待開盤 03-26 09:30:00 美东时间
106.91
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 106.91
- 總市值 91.93亿
- 52周最高 106.93
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 31.60
- 委 比 0.00%
- 總股本 8599.13万
- 歷史最高 106.93
- 量 比 0
- 振 幅 0.00%
- 歷史最低 2.01
- 每 手 1
- 風險率 18.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet Rewrites throughout, adds Merck's shares in paragraph 4, adds analyst comments in paragraphs 8, 13-16 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugma
03-25 18:54
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiry.
03-25 17:38
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
SAB Biotherapeutics reports progress on SAB-142's Phase 2b SAFEGUARD study for treating type 1 diabetes, with multiple patients dosed and enrollment on track to complete by end of 2026. Positive Phase 1 data highlight favorable safety profile and redosability. The company raised $175M in private placement to fully fund SAFEGUARD and has a strong cash position through 2028. Topline results expected in 2H2027.
03-09 21:16
UPDATE 3-Merck to create separate cancer business as Keytruda patent loss looms
UPDATE 3-Merck to create separate cancer business as Keytruda patent loss looms Adds details and background in paragraphs 6-7 Feb 23 (Reuters) - Merck MRK.N said on Monday it would split its human-health business into two units, creating a division for its cancer franchise led by blockbuster drug Ke
02-23 19:34
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results Co expects 2026 sales of $65.5 bln-$67 bln vs analysts' estimate $67.6 bln Reports Q4 sales of $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds analyst comments in paragraphs 5 and 10
02-03 19:40
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses Expects 2026 sales $65.5 bln-$67 bln; analysts estimating $67.6 bln Q4 sales were $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds shares in paragraph 3 By Michael Erman Feb 3 (Reut
02-03 19:40
Merck & Co. meldet für das vierte Quartal 2025 ein den Aktionären zurechenbares Nettoergebnis von 2.963 Mio. USD, ein Rückgang um 21 Prozent
Merck & Co. meldet für das vierte Quartal 2025 ein den Aktionären zurechenbares Nettoergebnis von 2.963 Mio. USD, ein Rückgang um 21 Prozent Merck & Co. Inc. hat die Finanzergebnisse für das vierte Quartal sowie das Gesamtjahr 2025 veröffentlicht. Das den Aktionären zurechenbare Nettoergebnis belief
02-03 19:31
Merck posts Q4 diluted EPS of USD 1.19, down 20%
Merck posts Q4 diluted EPS of USD 1.19, down 20% Merck & Co. Inc. reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, net income attributable to shareholders was USD 2.96 billion, with diluted earnings per share (EPS) of USD 1.19. For the full year 2025,
02-03 19:31
Merck forecasts 2026 sales below estimates on patent losses
Merck forecasts 2026 sales below estimates on patent losses Expects 2026 sales $65.5 bln-$67 bln; analysts estimating $67.6 bln Q4 sales were $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals By Michael Erman Feb 3 (Reuters) - Merck & Co MRK.N on Tuesday f
02-03 19:30
